Compare Globus Medical Inc. Class A Common Stock (GMED) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.09 (market cap $4.39B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 2.3× State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 42 Days on average.
| GMED | SJNK | |
|---|---|---|
Market Cap | $10.25B | $4.39B |
Volume | 1,108,124 | 1,736,904 |
Sector | Health | Fixed Income |
52-Week High | $96.82 | $25.57 |
52-Week Low | $58.33 | $24.10 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
SJNK trades at $24.19, showing minimal daily movement with a slight decline of 0.21%. The technical outlook appears bearish based on moving averages, though oscillators suggest neutral conditions. Recent corporate actions include consistent dividend payments, with three distributions scheduled for late 2026 ranging from $0.14 to $0.15 per share. Institutional activity shows mixed sentiment with both position reductions and maintained stakes among major holders.
The ETF faces headwinds from bearish technical indicators while maintaining dividend distributions. Key risks include interest rate sensitivity and institutional selling pressure. The neutral oscillator reading suggests potential for stabilization, but the overall technical picture warrants caution for near-term positioning in this high-yield bond ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
